573 related articles for article (PubMed ID: 28134791)
21. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer.
Harris AE; Metzler VM; Lothion-Roy J; Varun D; Woodcock CL; Haigh DB; Endeley C; Haque M; Toss MS; Alsaleem M; Persson JL; Gudas LJ; Rakha E; Robinson BD; Khani F; Martin LM; Moyer JE; Brownlie J; Madhusudan S; Allegrucci C; James VH; Rutland CS; Fray RG; Ntekim A; de Brot S; Mongan NP; Jeyapalan JN
Front Endocrinol (Lausanne); 2022; 13():1006101. PubMed ID: 36263323
[TBL] [Abstract][Full Text] [Related]
22. Steroid hormone synthetic pathways in prostate cancer.
Mostaghel EA
Transl Androl Urol; 2013 Sep; 2(3):212-227. PubMed ID: 25379460
[TBL] [Abstract][Full Text] [Related]
23. A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer.
Crowley F; Sterpi M; Buckley C; Margetich L; Handa S; Dovey Z
Res Rep Urol; 2021; 13():457-472. PubMed ID: 34235102
[TBL] [Abstract][Full Text] [Related]
24. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
25.
Fararjeh AS; Liu YN
Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31181727
[TBL] [Abstract][Full Text] [Related]
26. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
Cai Z; Chen W; Zhang J; Li H
Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
[TBL] [Abstract][Full Text] [Related]
27. Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer.
Ehsani M; David FO; Baniahmad A
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33810413
[TBL] [Abstract][Full Text] [Related]
28. Interplay between genomic alterations and androgen receptor signaling during prostate cancer development and progression.
Nyquist MD; Dehm SM
Horm Cancer; 2013 Apr; 4(2):61-9. PubMed ID: 23307762
[TBL] [Abstract][Full Text] [Related]
29. Effects of WNT/beta-catenin pathway activation on signaling through T-cell factor and androgen receptor in prostate cancer cell lines.
Cronauer MV; Schulz WA; Ackermann R; Burchardt M
Int J Oncol; 2005 Apr; 26(4):1033-40. PubMed ID: 15753999
[TBL] [Abstract][Full Text] [Related]
30. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
[TBL] [Abstract][Full Text] [Related]
31. Pre-existing Castration-resistant Prostate Cancer-like Cells in Primary Prostate Cancer Promote Resistance to Hormonal Therapy.
Cheng Q; Butler W; Zhou Y; Zhang H; Tang L; Perkinson K; Chen X; Jiang XS; McCall SJ; Inman BA; Huang J
Eur Urol; 2022 May; 81(5):446-455. PubMed ID: 35058087
[TBL] [Abstract][Full Text] [Related]
32. Androgen receptor signaling and spatial chromatin organization in castration-resistant prostate cancer.
Zhou T; Feng Q
Front Med (Lausanne); 2022; 9():924087. PubMed ID: 35966880
[TBL] [Abstract][Full Text] [Related]
33. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance.
Jamroze A; Chatta G; Tang DG
Cancer Lett; 2021 Oct; 518():1-9. PubMed ID: 34118355
[TBL] [Abstract][Full Text] [Related]
34. Beyond T and DHT - novel steroid derivatives capable of wild type androgen receptor activation.
Mostaghel EA
Int J Biol Sci; 2014; 10(6):602-13. PubMed ID: 24948873
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer.
Chen X; Liu J; Cheng L; Li C; Zhang Z; Bai Y; Wang R; Han T; Huang C; Kong Y; Feng F; Liu X
Prostate; 2020 Feb; 80(3):256-266. PubMed ID: 31856338
[TBL] [Abstract][Full Text] [Related]
36. Interplay between orphan nuclear receptors and androgen receptor-dependent or-independent growth signalings in prostate cancer.
Wang Y; Gao W; Li Y; Chow ST; Xie W; Zhang X; Zhou J; Chan FL
Mol Aspects Med; 2021 Apr; 78():100921. PubMed ID: 33121737
[TBL] [Abstract][Full Text] [Related]
37. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
38. Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer.
Wen S; Niu Y; Huang H
Asian J Urol; 2020 Jul; 7(3):203-218. PubMed ID: 33024699
[TBL] [Abstract][Full Text] [Related]
39. Androgen deprivation-induced NCoA2 promotes metastatic and castration-resistant prostate cancer.
Qin J; Lee HJ; Wu SP; Lin SC; Lanz RB; Creighton CJ; DeMayo FJ; Tsai SY; Tsai MJ
J Clin Invest; 2014 Nov; 124(11):5013-26. PubMed ID: 25295534
[TBL] [Abstract][Full Text] [Related]
40. CaV1.3 enhanced store operated calcium promotes resistance to androgen deprivation in prostate cancer.
O'Reilly D; Downing T; Kouba S; Potier-Cartereau M; McKenna DJ; Vandier C; Buchanan PJ
Cell Calcium; 2022 May; 103():102554. PubMed ID: 35193095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]